Erlend Bremertun Smeland

  • Principal investigator; MD/PhD
  • +47 913 88 199

Curriculum vitae

Erlend B. Smeland

Nationality: Norwegian
Date of birth: Oct. 5, 1955

Lymphoma Biology Group home page

K.G. Jebsen Centre for B cell malignancies home page


1987                 PhD, University of Oslo
1980                 MD, University of Oslo

Current positions

2009-               Director research, education and innovation, Oslo University Hospital
1998-               Side position: Professor II, Medical Faculty, University of Oslo
2017-               PI, Centre for B cell malignancies (K.G.Jebsen Centre)

Previous positions and research experience

1992-17         Group leader, Dept of Immunology, Inst for Cancer Research, Oslo University Hospital
2007-17         1/6 PIs at Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo (Centre of excellence)
2002-08         Director, Institute for Cancer Research
2000-             Member of the Coordinating Committee and site-PI in the Lymphoma/Leukemia Molecular Profiling Project (headed by Louis M. Staudt, M.D. Ph.D. National Cancer Institute)
2003-06         Side position: Research Coordinator Helse Sør
2007-09         Side position: Research Director Helse Sør-Øst
1995-04         Member of the Board, The Norwegian Cancer Society, chairman 2003-04
1992-02         Head, Dept of Immunology, Institute for Cancer Research, OUS
1987-92         Researcher, Dept of Immunology, Institute for Cancer Research, OUS
1983-87         PhD student, Dept of Immunology, Institute for Cancer Research, OUS                   

Key assignments

2015-               Member of the Board, Strategi HelseOmsorg21 (National Health Strategy)
2015-               Chairman, Research Council Oslo University Hospital.
2013-               Member of the Board, Inven2 (TTO for OUS and University of Oslo)
2013-               Member of the Steering committee, Institute for Experimental Medical Research, OUS
2012-18         Co-chairman of the Board, Norwegian Medical Cyclotrone Centre AS
2009-               Chairman, Research Leader Forum Oslo University Hospital and University of Oslo
2005-               Member of NSG (National Strategy Group for Health Research) (not member 2014-oct 2015, reappointed from nov 2015)
2005-               Member of the Board, Norwegian Radium Hospital Research Foundation
2003-               Member of Samarbeidsorganet University of Oslo /Helse Sør- Øst
2003-               Member of the Regional Health Authorities National Strategy Group for Research 

Commissions of trust

Member of several evaluation committees and committees regarding academic positions. Referee for various journals
Opponent for 18 PhD students
Chairman of the Board, Centre of Connected Care (Centre of research-driven innovation) 2017-
Chairman of the Board, The Norwegian Cancer Genome Consortium (2014-19)
Member of the steering committee, Personalized Medicine in the Health System (led by Helse Sør-Øst, 20134) and in the reference committee for the subsequent National strategy for personalized medicine in the health care system (Directorate of Health) 2015
Responsible for Research Strategy in Helse Sør-Øst (Regional Health Authority) 2007-9
Board member “FORNY”-program, The Norwegian Research Council, 2002 – 2003
Head, Evaluation committee regarding gene therapy in Norway, appointed by ”Senter for Medisinsk Metodevurdering”: Future role of gene therapy in the Norwegian health care (2000)


Current supervision:Main supervisor for 1 Postdoc (Yngvild Blaker)
Co-supervisor for 5 Postdocs and 1 PhD student
Past supervision: Main supervisor for 4 Postdoc, and 14 PhD-students Co-supervisor, 10 PhDs
Lecturing: Regular lectures for pre- and postgraduate students. Several invited lectures at national and international meetings. Lately, most of the international presentations regarding our work have been made by young scientist in the group.

Awards, and other professional merits

King Olav V’s Cancer Research Prize (2004)
Elected member of the Norwegian Academy of Science 2005
Prize excellent article OUS (bi-annual prize) 2014        

Areas of competence

I have a wide experience in research leadership and strategic work. I have been heavily involved in development of several research strategies, both at the institutional, regional and national level. In particular I was in charge of the research strategy for the Regional Health Autority South-East, after the merger of two regions into the major Healt Region in 2007. I have been part of the hospital leaderships with responsibility for research from 1996 to date, including the Norwegian Radium Hospital 1996-2005), the merged Riks-Radium Hospital (2005-8) and the merged Oslo University Hospital afer the fusion of the Riks-Radium Hospital with Ullevål and Aker University Hospitals (2009-). During the whole period I have headed a research group at Department of Immunology at Institute for Cancer Research (from 2018 associate group leader). I was head of the Institute (over 300 employees, 2002-8) before I was appointed research director for Oslo University Hospital.

I have a wide experience in translational lymphoma research and I have had a long-standing and close collaboration with the lymphoma clinicians and pathologists at our institution. The lymphoma milieu at our hospital has a strong reseach tradition and are constantly involved in 10-15 clinical trials. Our group has wide experience in functional studies and use of advanced flow cytometry and high-throughput analyses of genes and gene expression. We have developed a number of monoclonal antibodies against various CD antigens, and used these to characterize the antigens, for functional studies and for cell isolation using immunomagnetic beads. We have performed a number of in vitro culture studies of normal B cells and B cell progenitor cells to examine regulation of cell growth and cell death. During the later years, we have increasingly been involved in molecular profiling of B cell lymphoma using high-throughput analyses. We have been involved in the very successful LLMPP initiative since 2000, which has led to a number of articles in top journals. I am site-PI at our hospital in this collaboration. In addition, we have performed several in-house studies of follicular lymphoma and DLBCL. We have great experience through the established collaboration with the Stanford and Vanderbilt milieus, regarding the use of phospho-flow cytometry to explore basic and induced signalling in tumor cells and non-tumor immune cells and successfully used the mass cytometry/CyTOF technology for characterization of immune cells, which is now been established at the Institute.

Track record

Total publications and citations

Total career publications 193, 161 original papers, including co-authorship in top journals: N Engl J Med (4), Nature (4), Science (1) and Cancer Cell (2).

h-index 51

Total citations are 15079, without self-citations 14696 (Web of Science, april 2019).

Ten selected publications (last 10 years)

#Steen, C.B. et al.  A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy. Haematologica. Mar 7. pii: haematol.2018.209080. doi: 10.3324/haematol.2018.209080. [Epub ahead of print] (2019)
2  Scott, D.W. et al. New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies. Journal of Clinical Oncology.  ISSN 0732-183X.  35(15), s 1668- 1677 . doi: 10.1200/JCO.2016.70.7901 (2017)
3  #Josefsson, SEG et al. T cells expressing checkpoint receptor TIGIT are enriched in follicular lymphoma tumors and characterized by reversible suppression of T-cell receptor signaling. Clinical Cancer Research.  ISSN 1078-0432.  24(4), s 870- 881 . doi: 10.1158/1078-0432.CCR-17-2337 (2017)
4  Scott, D. W. et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 123, 1214-1217, doi:10.1182/blood-2013-11-536433 (2014).
5  Muppidi, J. R. et al. Loss of signalling via G alpha 13 in germinal centre B-cell-derived lymphoma. Nature516, 254-+, doi:10.1038/nature13765 (2014).
6  #Brodtkorb, M. et al. Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma. Blood123, 1051-1054, doi:10.1182/blood-2013-07-512392 (2014).
7  Schmitz, R. et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature490, 116-120, doi:10.1038/nature11378 (2012).
8  Ngo, V. N. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature470, 115-U133, doi:10.1038/nature09671 (2011).
9  #Eide, M. B. et al. Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. Blood116, 1489-1497, doi:10.1182/blood-2010-03-272278 (2010).
10 Davis, R. E. et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature463, 88-U97, doi:10.1038/nature08638 (2010). 

# First/last author from our group

Innovation and patents

I have contributed to characterization of several monoclonal antibodies, which have been licensed. I have contributed to development of methods for efficient isolation of CD34+ hematopoietic progenitor cells and CD19+ B cells, cells using immunomagnetic beads and to development of a method for detachment of beads. Kits for isolation of CD34+ and CD19+ cells have been commercialized by Dynal/Invitrogen. The anti-CD37 monoclonal antibody HH1, which was developed in our lab and characterized during my PhD work, has been radiolabelled via a spin-off company (Nordic Nanovector) and is tried out for therapy (6 first patients have been treated).

Since 2005 I am a coinventor of 6 patents and patent applications from the international lymphoma and leukemia profiling project (LLMPP). This consortium has developed array-based methods for distinction of aggressive B cell lymphomas, using fresh frozen tissue or paraffin-embedded tissue, which allows precise diagnosis and prognostic information of major types of aggressive B cell lymphoma, including mantle cell lymphoma, Burkitts lymphoma and three different and clinically relevant molecular subtypes of diffuse B cell lymphoma, which is the major type of B cell lymphoma.

I am also coinventor on a patent application describing a novel chimeric antigen receptor (CAR) targeting CD37, a pan B cell antigen expressed on most B cell lymphomas, using the anti-CD37 mAb (HH1) (2015).


Publications 2021

Oksvold MP, Berglund UW, Gad H, Bai B, Stokke T, Rein ID, Pham T, Sanjiv K, Øy GF, Norum JH, Smeland EB, Myklebust JH, Helleday T, Våtsveen TK (2021)
Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma
Sci Rep, 11 (1), 6317
DOI 10.1038/s41598-021-85613-8, PubMed 33737576

Publications 2020

Köksal H, Dillard P, Juzeniene A, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S (2020)
Combinatorial CAR design improves target restriction
J Biol Chem, 296, 100116
DOI 10.1074/jbc.RA120.016234, PubMed 33234592

Wise JF, Nakken S, Steen CB, Vodák D, Trøen G, Johannessen B, Lingjærde OC, Hilden V, Blaker YN, Bai B, Aasheim LB, Pasanen A, Lorenz S, Sveen A, Lothe RA, Myklebost O, Leppä S, Meza-Zepeda LA, Beiske K, Lawrence MS, Hovig E, Myklebust JH, Smeland EB, Holte H (2020)
Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
Blood Adv, 4 (9), 1859-1866
DOI 10.1182/bloodadvances.2019001325, PubMed 32374878

Publications 2019

Huse K, Wogsland CE, Polikowsky HG, Diggins KE, Smeland EB, Myklebust JH, Irish JM (2019)
Human Germinal Center B Cells Differ from Naïve and Memory B Cells in CD40 Expression and CD40L-Induced Signaling Response
Cytometry A, 95 (4), 442-449
DOI 10.1002/cyto.a.23737, PubMed 30838773

Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH (2019)
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
Cancer Immunol Res, 7 (3), 355-362
DOI 10.1158/2326-6066.CIR-18-0351, PubMed 30659053

Köksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fåne A, Blaker YN, Beiske K, Huse K, Kolstad A, Holte H, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S (2019)
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
Blood Adv, 3 (8), 1230-1243
DOI 10.1182/bloodadvances.2018029678, PubMed 30979721

Steen CB, Leich E, Myklebust JH, Lockmer S, Wise JF, Wahlin BE, Østenstad B, Liestøl K, Kimby E, Rosenwald A, Smeland EB, Holte H, Lingjærde OC, Brodtkorb M (2019)
A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy
Haematologica, 104 (10), e460-e464
DOI 10.3324/haematol.2018.209080, PubMed 30846496

Publications 2018

Holte H, Beiske K, Boyle M, Trøen G, Blaker YN, Myklebust J, Kvaløy S, Rosenwald A, Lingjaerde OC, Rimsza LM, Smeland EB, Scott DW, Kolstad A (2018)
The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy
Br J Haematol, 183 (2), 225-234
DOI 10.1111/bjh.15518, PubMed 30080252

Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, Braziel RM, Delabie J, Weisenburger DD, Song JY, Chan WC, Cook JR, Fu K, Greiner T, Smeland E, Holte H, Savage KJ, Glinsmann-Gibson BJ, Gascoyne RD, Staudt LM, Jaffe ES, Connors JM, Scott DW, Steidl C, Rimsza LM (2018)
Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens
Blood, 132 (22), 2401-2405
DOI 10.1182/blood-2018-05-851154, PubMed 30257882

Våtsveen TK, Myhre MR, Steen CB, Wälchli S, Lingjærde OC, Bai B, Dillard P, Theodossiou TA, Holien T, Sundan A, Inderberg EM, Smeland EB, Myklebust JH, Oksvold MP (2018)
Artesunate shows potent anti-tumor activity in B-cell lymphoma
J Hematol Oncol, 11 (1), 23
DOI 10.1186/s13045-018-0561-0, PubMed 29458389

Publications 2017

Bollum LK, Huse K, Oksvold MP, Bai B, Hilden VI, Forfang L, Yoon SO, Wälchli S, Smeland EB, Myklebust JH (2017)
BMP-7 induces apoptosis in human germinal center B cells and is influenced by TGF-β receptor type I ALK5
PLoS One, 12 (5), e0177188
DOI 10.1371/journal.pone.0177188, PubMed 28489883

Josefsson SE, Huse K, Kolstad A, Beiske K, Pende D, Steen CB, Inderberg EM, Lingjærde OC, Østenstad B, Smeland EB, Levy R, Irish JM, Myklebust JH (2017)
T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
Clin Cancer Res, 24 (4), 870-881
DOI 10.1158/1078-0432.CCR-17-2337, PubMed 29217528

Mäkitie A, Ruuskanen M, Bentzen J, Brun E, Gebre-Medhin M, Friesland S, Marsk E, Hammarstedt-Nordenvall L, Gille E, Reizenstein J, Adell G, Farnebo L, Rzepecki J, Haugen H, Söderström K, Zackrisson B, Bergström S, Lödén B, Cederblad L, Laurell G, Smeland E, Folkvard Evensen J, Lund JÅ, Tøndel H, Karlsdottir Å et al. (2017)
The management and survival outcomes of nasopharyngeal cancer in the Nordic countries
Acta Oncol, 57 (4), 557-560
DOI 10.1080/0284186X.2017.1408961, PubMed 29202641

Scott DW, Abrisqueta P, Wright GW, Slack GW, Mottok A, Villa D, Jares P, Rauert-Wunderlich H, Royo C, Clot G, Pinyol M, Boyle M, Chan FC, Braziel RM, Chan WC, Weisenburger DD, Cook JR, Greiner TC, Fu K, Ott G, Delabie J, Smeland EB, Holte H, Jaffe ES, Steidl C et al. (2017)
New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies
J Clin Oncol, 35 (15), 1668-1677
DOI 10.1200/JCO.2016.70.7901, PubMed 28291392

Publications 2016

Blaker YN, Spetalen S, Brodtkorb M, Lingjaerde OC, Beiske K, Østenstad B, Sander B, Wahlin BE, Melen CM, Myklebust JH, Holte H, Delabie J, Smeland EB (2016)
The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era
Br J Haematol, 175 (1), 102-14
DOI 10.1111/bjh.14201, PubMed 27341313

Publications 2015

Blaker YN, Brodtkorb M, Maddison J, Hveem TS, Nesheim JA, Mohn HM, Kolstad A, Geisler CH, Liestøl K, Smeland EB, Holte H, Delabie J, Danielsen H (2015)
Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma
Histopathology, 67 (1), 62-9
DOI 10.1111/his.12624, PubMed 25431344

Malecka A, Tierens A, Østlie I, Schmitz R, Trøen G, Spetalen S, Staudt LM, Smeland E, Holte H, Delabie J (2015)
Primary diffuse large B-cell lymphoma associated with clonally-related monoclonal B lymphocytosis indicates a common precursor cell
Haematologica, 100 (10), e415-8
DOI 10.3324/haematol.2015.126656, PubMed 26001788

Oksvold MP, Duyvestyn JM, Dagger SA, Taylor SJ, Forfang L, Myklebust JH, Smeland EB, Langdon WY (2015)
The targeting of human and mouse B lymphocytes by dasatinib
Exp Hematol, 43 (5), 352-363.e4
DOI 10.1016/j.exphem.2015.01.008, PubMed 25641047

Publications 2014

Bethge N, Honne H, Andresen K, Hilden V, Trøen G, Liestøl K, Holte H, Delabie J, Lind GE, Smeland EB (2014)
A gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma
PLoS One, 9 (9), e104249
DOI 10.1371/journal.pone.0104249, PubMed 25226156

Blaker YN, Eide MB, Liestøl K, Lauritzsen GF, Kolstad A, Fosså A, Smeland EB, Holte H (2014)
High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era
Leuk Lymphoma, 55 (10), 2319-27
DOI 10.3109/10428194.2013.871632, PubMed 24432894

Fiskvik I, Beiske K, Delabie J, Yri O, Spetalen S, Karjalainen-Lindsberg ML, Leppä S, Liestøl K, Smeland EB, Holte H (2014)
Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma
Leuk Lymphoma, 56 (6), 1742-9
DOI 10.3109/10428194.2014.970550, PubMed 25284491

Muppidi JR, Schmitz R, Green JA, Xiao W, Larsen AB, Braun SE, An J, Xu Y, Rosenwald A, Ott G, Gascoyne RD, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Vaidehi N, Staudt LM, Cyster JG (2014)
Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma
Nature, 516 (7530), 254-8
DOI 10.1038/nature13765, PubMed 25274307

Oksvold MP, Kullmann A, Forfang L, Kierulf B, Li M, Brech A, Vlassov AV, Smeland EB, Neurauter A, Pedersen KW (2014)
Expression of B-cell surface antigens in subpopulations of exosomes released from B-cell lymphoma cells
Clin Ther, 36 (6), 847-862.e1
DOI 10.1016/j.clinthera.2014.05.010, PubMed 24952935

Riihijärvi S, Fiskvik I, Taskinen M, Vajavaara H, Tikkala M, Yri O, Karjalainen-Lindsberg ML, Delabie J, Smeland E, Holte H, Leppä S (2014)
Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial
Haematologica, 100 (2), 238-45
DOI 10.3324/haematol.2014.113472, PubMed 25381134

Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Smeland EB, Mottok A, Braziel RM, Ott G, Delabie J, Tubbs RR, Cook JR, Weisenburger DD, Greiner TC, Glinsmann-Gibson BJ, Fu K, Staudt LM, Gascoyne RD, Rimsza LM (2014)
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
Blood, 123 (8), 1214-7
DOI 10.1182/blood-2013-11-536433, PubMed 24398326

Yang Y, Schmitz R, Mitala J, Whiting A, Xiao W, Ceribelli M, Wright GW, Zhao H, Yang Y, Xu W, Rosenwald A, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Wiestner A et al. (2014)
Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms
Cancer Discov, 4 (4), 480-93
DOI 10.1158/2159-8290.CD-13-0915, PubMed 24491438

Publications 2013

Bethge N, Honne H, Hilden V, Trøen G, Eknæs M, Liestøl K, Holte H, Delabie J, Smeland EB, Lind GE (2013)
Identification of highly methylated genes across various types of B-cell non-hodgkin lymphoma
PLoS One, 8 (11), e79602
DOI 10.1371/journal.pone.0079602, PubMed 24260260

Bethge N, Lothe RA, Honne H, Andresen K, Trøen G, Eknæs M, Liestøl K, Holte H, Delabie J, Smeland EB, Lind GE (2013)
Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma
Epigenetics, 9 (3), 428-36
DOI 10.4161/epi.27554, PubMed 24362313

Bödör C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM, Clear A, Montoto S, Matthews J, Iqbal S, Rajnai H, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Braziel RM, Staudt LM, Wright G, Lister TA et al. (2013)
EZH2 mutations are frequent and represent an early event in follicular lymphoma
Blood, 122 (18), 3165-8
DOI 10.1182/blood-2013-04-496893, PubMed 24052547

Brodtkorb M, Lingjærde OC, Huse K, Trøen G, Hystad M, Hilden VI, Myklebust JH, Leich E, Rosenwald A, Delabie J, Holte H, Smeland EB (2013)
Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma
Blood, 123 (7), 1051-4
DOI 10.1182/blood-2013-07-512392, PubMed 24357726

Fiskvik I, Aamot HV, Delabie J, Smeland EB, Stokke T, Heim S, Holte H (2013)
Karyotyping of diffuse large B-cell lymphomas: loss of 17p is associated with poor patient outcome
Eur J Haematol, 91 (4), 332-8
DOI 10.1111/ejh.12171, PubMed 23859481

Wahlin BE, Sundström C, Sander B, Christensson B, Jeppsson-Ahlberg Å, Hjalmarsson E, Holte H, Østenstad B, Brown PD, Smeland EB, Kimby E (2013)
Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy
Leuk Lymphoma, 55 (2), 288-95
DOI 10.3109/10428194.2013.802778, PubMed 23662992

Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H (2013)
Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab
Leuk Lymphoma, 54 (10), 2205-14
DOI 10.3109/10428194.2013.774392, PubMed 23391141

Publications 2012

Bakkebø M, Huse K, Hilden VI, Forfang L, Myklebust JH, Smeland EB, Oksvold MP (2012)
SARA is dispensable for functional TGF-β signaling
FEBS Lett, 586 (19), 3367-72
DOI 10.1016/j.febslet.2012.07.027, PubMed 22819827

Huse K, Bakkebø M, Wälchli S, Oksvold MP, Hilden VI, Forfang L, Bredahl ML, Liestøl K, Alizadeh AA, Smeland EB, Myklebust JH (2012)
Role of Smad proteins in resistance to BMP-induced growth inhibition in B-cell lymphoma
PLoS One, 7 (10), e46117
DOI 10.1371/journal.pone.0046117, PubMed 23049692

Oksvold MP, Pedersen NM, Forfang L, Smeland EB (2012)
Effect of cycloheximide on epidermal growth factor receptor trafficking and signaling
FEBS Lett, 586 (20), 3575-81
DOI 10.1016/j.febslet.2012.08.022, PubMed 22971756

Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES et al. (2012)
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
Nature, 490 (7418), 116-20
DOI 10.1038/nature11378, PubMed 22885699

Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H (2012)
Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma
Leuk Lymphoma, 53 (10), 1934-44
DOI 10.3109/10428194.2012.682307, PubMed 22475179

Publications 2011

Huse K, Bakkebø M, Oksvold MP, Forfang L, Hilden VI, Stokke T, Smeland EB, Myklebust JH (2011)
Bone morphogenetic proteins inhibit CD40L/IL-21-induced Ig production in human B cells: differential effects of BMP-6 and BMP-7
Eur J Immunol, 41 (11), 3135-45
DOI 10.1002/eji.201141558, PubMed 21898381

Josefsen D, Forfang L, Dyrhaug M, Blystad AK, Stokke T, Smeland EB, Kvalheim G (2011)
Side population cells in highly enriched CD34-positive cells from peripheral blood progenitor cells identify an immature subtype of hematopoietic progenitor cells but do not predict time to engraftment in patients treated with high-dose therapy
Eur J Haematol, 87 (6), 494-502
DOI 10.1111/j.1600-0609.2011.01681.x, PubMed 21752097

Malumbres R, Fresquet V, Roman-Gomez J, Bobadilla M, Robles EF, Altobelli GG, Calasanz MJ, Smeland EB, Aznar MA, Agirre X, Martin-Palanco V, Prosper F, Lossos IS, Martinez-Climent JA (2011)
LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome
Haematologica, 96 (7), 980-6
DOI 10.3324/haematol.2011.040568, PubMed 21459790

Wahlin BE, Yri OE, Kimby E, Holte H, Delabie J, Smeland EB, Sundström C, Christensson B, Sander B (2011)
Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times
Br J Haematol, 156 (2), 225-33
DOI 10.1111/j.1365-2141.2011.08942.x, PubMed 22126847

Publications 2010

Bakkebø M, Huse K, Hilden VI, Smeland EB, Oksvold MP (2010)
TGF-β-induced growth inhibition in B-cell lymphoma correlates with Smad1/5 signalling and constitutively active p38 MAPK
BMC Immunol, 11, 57
DOI 10.1186/1471-2172-11-57, PubMed 21092277

Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E et al. (2010)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Nature, 463 (7277), 88-92
DOI 10.1038/nature08638, PubMed 20054396

Eide MB, Liestøl K, Lingjaerde OC, Hystad ME, Kresse SH, Meza-Zepeda L, Myklebost O, Trøen G, Aamot HV, Holte H, Smeland EB, Delabie J (2010)
Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones
Blood, 116 (9), 1489-97
DOI 10.1182/blood-2010-03-272278, PubMed 20505157

Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI et al. (2010)
Oncogenically active MYD88 mutations in human lymphoma
Nature, 470 (7332), 115-9
DOI 10.1038/nature09671, PubMed 21179087

Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao H, Yang Y, Lamy L, Davis RE, Xiao W, Powell J, Maloney D, Thomas CJ, Möller P, Rosenwald A, Ott G, Muller-Hermelink HK, Savage K, Connors JM et al. (2010)
Cooperative epigenetic modulation by cancer amplicon genes
Cancer Cell, 18 (6), 590-605
DOI 10.1016/j.ccr.2010.11.013, PubMed 21156283

Smeland EB, Vartdal F, Wisløff F (2010)
[Leadership and academic competence]
Tidsskr Nor Laegeforen, 130 (6), 591
DOI 10.4045/tidsskr.10.0217, PubMed 20348994

Smeland EB, Vartdal F, Wisløff F (2010)
[Close cooperation, but not oversteering]
Tidsskr Nor Laegeforen, 130 (6), 590-1
DOI 10.4045/tidsskr.10.0153, PubMed 20348990

Publications 2009

Holte H, Kvaløy S, Delabie J, Trøen G, Smeland EB (2009)
[Molecular diagnosis of malignant lymphomas]
Tidsskr Nor Laegeforen, 129 (22), 2352-6
DOI 10.4045/tidsskr.09.0704, PubMed 19935935

O'Riain C, O'Shea DM, Yang Y, Le Dieu R, Gribben JG, Summers K, Yeboah-Afari J, Bhaw-Rosun L, Fleischmann C, Mein CA, Crook T, Smith P, Kelly G, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Johnson N, Gascoyne RD, Reimer S, Braziel RM, Wright GW, Staudt LM et al. (2009)
Array-based DNA methylation profiling in follicular lymphoma
Leukemia, 23 (10), 1858-66
DOI 10.1038/leu.2009.114, PubMed 19587707

Publications 2008

Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Chan WC, Staudt LM (2008)
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma
Science, 319 (5870), 1676-9
DOI 10.1126/science.1153629, PubMed 18323416

Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G et al. (2008)
Stromal gene signatures in large-B-cell lymphomas
N Engl J Med, 359 (22), 2313-23
DOI 10.1056/NEJMoa0802885, PubMed 19038878

Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM (2008)
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
Proc Natl Acad Sci U S A, 105 (36), 13520-5
DOI 10.1073/pnas.0804295105, PubMed 18765795

O'Shea D, O'Riain C, Taylor C, Waters R, Carlotti E, Macdougall F, Gribben J, Rosenwald A, Ott G, Rimsza LM, Smeland EB, Johnson N, Campo E, Greiner TC, Chan WC, Gascoyne RD, Wright G, Staudt LM, Lister TA, Fitzgibbon J (2008)
The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival
Blood, 112 (8), 3126-9
DOI 10.1182/blood-2008-05-154013, PubMed 18628487

Publications 2007

Hystad ME, Myklebust JH, Bø TH, Sivertsen EA, Rian E, Forfang L, Munthe E, Rosenwald A, Chiorazzi M, Jonassen I, Staudt LM, Smeland EB (2007)
Characterization of early stages of human B cell development by gene expression profiling
J Immunol, 179 (6), 3662-71
DOI 10.4049/jimmunol.179.6.3662, PubMed 17785802

Lenz G, Nagel I, Siebert R, Roschke AV, Sanger W, Wright GW, Dave SS, Tan B, Zhao H, Rosenwald A, Muller-Hermelink HK, Gascoyne RD, Campo E, Jaffe ES, Smeland EB, Fisher RI, Kuehl WM, Chan WC, Staudt LM (2007)
Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma
J Exp Med, 204 (3), 633-43
DOI 10.1084/jem.20062041, PubMed 17353367

Sivertsen EA, Huse K, Hystad ME, Kersten C, Smeland EB, Myklebust JH (2007)
Inhibitory effects and target genes of bone morphogenetic protein 6 in Jurkat TAg cells
Eur J Immunol, 37 (10), 2937-48
DOI 10.1002/eji.200636759, PubMed 17899540

Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, Nakayama K, Liu H, Rosenwald A, Muller-Hermelink HK, Ott G, Chan WC, Greiner TC, Weisenburger DD, Vose J, Armitage JO, Gascoyne RD, Connors JM, Campo E, Montserrat E, Bosch F, Smeland EB, Kvaloy S, Holte H, Delabie J, Fisher RI et al. (2007)
Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival
Blood, 109 (11), 4599-606
DOI 10.1182/blood-2006-08-039859, PubMed 17299095

Publications 2006

Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB et al. (2006)
Molecular diagnosis of Burkitt's lymphoma
N Engl J Med, 354 (23), 2431-42
DOI 10.1056/NEJMoa055759, PubMed 16760443

Kersten C, Dosen G, Myklebust JH, Sivertsen EA, Hystad ME, Smeland EB, Rian E (2006)
BMP-6 inhibits human bone marrow B lymphopoiesis--upregulation of Id1 and Id3
Exp Hematol, 34 (1), 72-81
DOI 10.1016/j.exphem.2005.09.010, PubMed 16413393

Sivertsen EA, Galteland E, Mu D, Holte H, Meza-Zepeda L, Myklebost O, Patzke S, Smeland EB, Stokke T (2006)
Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas
Leukemia, 20 (3), 539-42
DOI 10.1038/sj.leu.2404094, PubMed 16437153

Sivertsen EA, Hystad ME, Gutzkow KB, Døsen G, Smeland EB, Blomhoff HK, Myklebust JH (2006)
PI3K/Akt-dependent Epo-induced signalling and target genes in human early erythroid progenitor cells
Br J Haematol, 135 (1), 117-28
DOI 10.1111/j.1365-2141.2006.06252.x, PubMed 16965383

Publications 2005

Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R et al. (2005)
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction
Blood, 106 (9), 3183-90
DOI 10.1182/blood-2005-04-1399, PubMed 16046532

Kersten C, Sivertsen EA, Hystad ME, Forfang L, Smeland EB, Myklebust JH (2005)
BMP-6 inhibits growth of mature human B cells; induction of Smad phosphorylation and upregulation of Id1
BMC Immunol, 6, 9
DOI 10.1186/1471-2172-6-9, PubMed 15877825

Torlakovic E, Malecka A, Myklebust JH, Tierens A, Aasheim HC, Nesland JM, Smeland E, Kvaløy S, Delabie J (2005)
PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promotor
J Pathol, 206 (3), 312-9
DOI 10.1002/path.1777, PubMed 15892171

Publications 2004

Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA et al. (2004)
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
N Engl J Med, 351 (21), 2159-69
DOI 10.1056/NEJMoa041869, PubMed 15548776

Fosså A, Alsøe L, Crameri R, Funderud S, Gaudernack G, Smeland EB (2004)
Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display
Cancer Immunol Immunother, 53 (5), 431-8
DOI 10.1007/s00262-003-0458-8, PubMed 14747957

Fosså A, Berner A, Fosså SD, Hernes E, Gaudernack G, Smeland EB (2004)
NY-ESO-1 protein expression and humoral immune responses in prostate cancer
Prostate, 59 (4), 440-7
DOI 10.1002/pros.20025, PubMed 15065093

Kersten C, Delabie J, Gaudernack G, Smeland EB, Fosså A (2004)
Analysis of the autoantibody repertoire in Burkitt's lymphoma patients: frequent response against the transcription factor ATF-2
Cancer Immunol Immunother, 53 (12), 1119-26
DOI 10.1007/s00262-004-0558-0, PubMed 15185015

Publications 2003

Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R et al. (2003)
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
J Exp Med, 198 (6), 851-62
DOI 10.1084/jem.20031074, PubMed 12975453

Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC et al. (2003)
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
Cancer Cell, 3 (2), 185-97
DOI 10.1016/s1535-6108(03)00028-x, PubMed 12620412

Publications 2002

Myklebust JH, Blomhoff HK, Rusten LS, Stokke T, Smeland EB (2002)
Activation of phosphatidylinositol 3-kinase is important for erythropoietin-induced erythropoiesis from CD34(+) hematopoietic progenitor cells
Exp Hematol, 30 (9), 990-1000
DOI 10.1016/s0301-472x(02)00868-8, PubMed 12225790

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ et al. (2002)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
N Engl J Med, 346 (25), 1937-47
DOI 10.1056/NEJMoa012914, PubMed 12075054

Wang J, Delabie J, Aasheim H, Smeland E, Myklebost O (2002)
Clustering of the SOM easily reveals distinct gene expression patterns: results of a reanalysis of lymphoma study
BMC Bioinformatics, 3, 36
DOI 10.1186/1471-2105-3-36, PubMed 12445336

Publications 2001

Blystad AK, Holte H, Kvaløy S, Smeland E, Delabie J, Kvalheim G (2001)
High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells
Bone Marrow Transplant, 28 (9), 849-57
DOI 10.1038/sj.bmt.1703244, PubMed 11781645

Hovig E, Myklebost O, Aamdal S, Smeland EB (2001)
[Gene therapy in cancer]
Tidsskr Nor Laegeforen, 121 (4), 482-8
PubMed 11255868

Lyngstadaas A, Smeland EB (2001)
[Gene therapy--status and recommendations in Norwegian health care system]
Tidsskr Nor Laegeforen, 121 (3), 343-8
PubMed 11242880

Stokke T, DeAngelis P, Smedshammer L, Galteland E, Steen HB, Smeland EB, Delabie J, Holte H (2001)
Loss of chromosome 11q21-23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma
Br J Cancer, 85 (12), 1900-13
DOI 10.1054/bjoc.2001.2164, PubMed 11747333

Publications 2000

Aasheim HC, Munthe E, Funderud S, Smeland EB, Beiske K, Logtenberg T (2000)
A splice variant of human ephrin-A4 encodes a soluble molecule that is secreted by activated human B lymphocytes
Blood, 95 (1), 221-30
DOI 10.1182/blood.V95.1.221.001k01_221_230, PubMed 10607706

Fosså A, Siebert R, Aasheim HC, Maelandsmo GM, Berner A, Fosså SD, Paus E, Smeland EB, Gaudernack G (2000)
Identification of nucleolar protein No55 as a tumour-associated autoantigen in patients with prostate cancer
Br J Cancer, 83 (6), 743-9
DOI 10.1054/bjoc.2000.1365, PubMed 10952778

Josefsen D, Myklebust JH, Lømo J, Sioud M, Blomhoff HK, Smeland EB (2000)
Differential expression of bcl-2 homologs in human CD34(+) hematopoietic progenitor cells induced to differentiate into erythroid or granulocytic cells
Stem Cells, 18 (4), 261-72
DOI 10.1634/stemcells.18-4-261, PubMed 10924092

Myklebust JH, Smeland EB, Josefsen D, Sioud M (2000)
Protein kinase C-alpha isoform is involved in erythropoietin-induced erythroid differentiation of CD34(+) progenitor cells from human bone marrow
Blood, 95 (2), 510-8
DOI 10.1182/blood.V95.2.510, PubMed 10627456

Naderi S, Gützkow KB, Christoffersen J, Smeland EB, Blomhoff HK (2000)
cAMP-mediated growth inhibition of lymphoid cells in G1: rapid down-regulation of cyclin D3 at the level of translation
Eur J Immunol, 30 (6), 1757-68
DOI 10.1002/1521-4141(200006)30:6<1757::AID-IMMU1757>3.0.CO;2-N, PubMed 10898514

Smeland EB (2000)
Gene therapy: status and potential in clinical medicine
In SMM-rapport, Senteret, Oslo, nr 7/2000, 120 s.
BIBSYS 010526498, ISBN 82-14-02179-0

Smeland EB (2000)
Genterapi: status og fremtidige muligheter innen klinisk medisin
In SMM-rapport, Senteret, Oslo, 2000:1, 124 s.
BIBSYS 000268178, ISBN 82-14-01814-5

Stokke T, Galteland E, Holte H, Smedshammer L, Suo Z, Smeland EB, Børresen-Dale AL, DeAngelis P, Steen HB (2000)
Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin's lymphoma
Int J Cancer, 89 (4), 313-24
DOI 10.1002/1097-0215(20000720)89:4<313::aid-ijc1>;2-d, PubMed 10956404

Publications 1999

Davidson B, Risberg B, Berner A, Smeland EB, Torlakovic E (1999)
Evaluation of lymphoid cell populations in cytology specimens using flow cytometry and polymerase chain reaction
Diagn Mol Pathol, 8 (4), 183-8
DOI 10.1097/00019606-199912000-00003, PubMed 10617274

Holte H, Suo Z, Smeland EB, Kvaløy S, Langholm R, Stokke T (1999)
Prognostic value of lymphoma-specific S-phase fraction compared with that of other cell proliferation markers
Acta Oncol, 38 (4), 495-503
DOI 10.1080/028418699432040, PubMed 10418718

Josefsen D, Blomhoff HK, Lømo J, Blystad AK, Smeland EB (1999)
Retinoic acid induces apoptosis of human CD34+ hematopoietic progenitor cells: involvement of retinoic acid receptors and retinoid X receptors depends on lineage commitment of the hematopoietic progenitor cells
Exp Hematol, 27 (4), 642-53
DOI 10.1016/s0301-472x(98)00073-3, PubMed 10210322

Josefsen D, Myklebust JH, Lynch DH, Stokke T, Blomhoff HK, Smeland EB (1999)
Fas ligand promotes cell survival of immature human bone marrow CD34+CD38- hematopoietic progenitor cells by suppressing apoptosis
Exp Hematol, 27 (9), 1451-9
DOI 10.1016/s0301-472x(99)00073-9, PubMed 10480436

Myklebust JH, Josefsen D, Blomhoff HK, Levy FO, Naderi S, Reed JC, Smeland EB (1999)
Activation of the cAMP signaling pathway increases apoptosis in human B-precursor cells and is associated with downregulation of Mcl-1 expression
J Cell Physiol, 180 (1), 71-80
DOI 10.1002/(SICI)1097-4652(199907)180:1<71::AID-JCP8>3.0.CO;2-N, PubMed 10362019

Naderi S, Blomhoff R, Myklebust J, Smeland EB, Erikstein B, Norum KR, Blomhoff HK (1999)
Lovastatin inhibits G1/S transition of normal human B-lymphocytes independent of apoptosis
Exp Cell Res, 252 (1), 144-53
DOI 10.1006/excr.1999.4608, PubMed 10502407

Smeland E (1999)
[University function at the central hospital in Akershus]
Tidsskr Nor Laegeforen, 119 (11), 1647
PubMed 10385812

Publications 1998

Aurlien E, Holte H, Pharo A, Kvaløy S, Jakobsen E, Smeland EB, Kvalheim G (1998)
Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma
Bone Marrow Transplant, 21 (9), 873-8
DOI 10.1038/sj.bmt.1701192, PubMed 9613778

Heim S, Smeland EB (1998)
[Molecular genetic diagnosis of leukemias and lymphomas]
Tidsskr Nor Laegeforen, 118 (16), 2511-8
PubMed 9667131

Lømo J, Smeland EB, Ulven S, Natarajan V, Blomhoff R, Gandhi U, Dawson MI, Blomhoff HK (1998)
RAR-, not RXR, ligands inhibit cell activation and prevent apoptosis in B-lymphocytes
J Cell Physiol, 175 (1), 68-77
DOI 10.1002/(SICI)1097-4652(199804)175:1<68::AID-JCP8>3.0.CO;2-A, PubMed 9491782

Ly B, Hammerstrøm J, Bergheim J, Dahl IM, Grøttum KA, Lødemel B, Baklien K, Smeland E (1998)
[Chronic lymphatic leukemia. Immunophenotyping as an aid to correct diagnosis]
Tidsskr Nor Laegeforen, 118 (2), 233-7
PubMed 9485618

Stokke T, Holte H, Smedshammer L, Smeland EB, Kaalhus O, Steen HB (1998)
Proliferation and apoptosis in malignant and normal cells in B-cell non-Hodgkin's lymphomas
Br J Cancer, 77 (11), 1832-8
DOI 10.1038/bjc.1998.304, PubMed 9667654

Stokke T, Smeland EB, Kvaløy S, Holte H (1998)
Tumour cell proliferation, but not apoptosis, predicts survival in B-cell non-Hodgkin's lymphomas
Br J Cancer, 77 (11), 1839-41
DOI 10.1038/bjc.1998.305, PubMed 9667655

Publications 1997

Aasheim HC, Pedeutour F, Smeland EB (1997)
Characterization, expression and chromosomal localization of a human gene homologous to the mouse Lsc oncogene, with strongest expression in hematopoetic tissues
Oncogene, 14 (14), 1747-52
DOI 10.1038/sj.onc.1200994, PubMed 9135076

Hallan E, Blomhoff HK, Smeland EB, Lømo J (1997)
Involvement of ICE (Caspase) family in gamma-radiation-induced apoptosis of normal B lymphocytes
Scand J Immunol, 46 (6), 601-8
DOI 10.1046/j.1365-3083.1997.d01-173.x, PubMed 9420624

Kvingedal AM, Smeland EB (1997)
A novel putative G-protein-coupled receptor expressed in lung, heart and lymphoid tissue
FEBS Lett, 407 (1), 59-62
DOI 10.1016/s0014-5793(97)00278-0, PubMed 9141481

Lømo J, Blomhoff HK, Jacobsen SE, Krajewski S, Reed JC, Smeland EB (1997)
Interleukin-13 in combination with CD40 ligand potently inhibits apoptosis in human B lymphocytes: upregulation of Bcl-xL and Mcl-1
Blood, 89 (12), 4415-24
PubMed 9192766

Rasmussen AM, Horejsí V, Levy FO, Blomhoff HK, Smeland EB, Beiske K, Michaelsen TE, Gaudernack G, Funderud S (1997)
CDw78--a determinant on a major histocompatibility complex class II subpopulation that can be induced to associate with the cytoskeleton
Eur J Immunol, 27 (12), 3206-13
DOI 10.1002/eji.1830271218, PubMed 9464807

Smeland E (1997)
[Changing physician's role]
Tidsskr Nor Laegeforen, 117 (29), 4290
PubMed 9441481

Publications 1996

Kvalheim G, Pharo A, Holte H, Jakobsen E, Erikstein B, Kvaløy S, Beiske K, Nesland JM, Smeland EB (1996)
[High-dose therapy of cancer with CD34 positive cells as stem cell support]
Tidsskr Nor Laegeforen, 116 (21), 2542-6
PubMed 8928121

Kvalheim G, Wang MY, Pharo A, Holte H, Jacobsen E, Beiske K, Kvaløy S, Smeland E, Funderud S, Fodstad O (1996)
Purging of tumor cells from leukapheresis products: experimental and clinical aspects
J Hematother, 5 (4), 427-36
DOI 10.1089/scd.1.1996.5.427, PubMed 8877718

Levy FO, Rasmussen AM, Taskén K, Skålhegg BS, Huitfeldt HS, Funderud S, Smeland EB, Hansson V (1996)
Cyclic AMP-dependent protein kinase (cAK) in human B cells: co-localization of type I cAK (RI alpha 2 C2) with the antigen receptor during anti-immunoglobulin-induced B cell activation
Eur J Immunol, 26 (6), 1290-6
DOI 10.1002/eji.1830260617, PubMed 8647207

Lømo J, Smeland EB, Krajewski S, Reed JC, Blomhoff HK (1996)
Expression of the Bcl-2 homologue Mcl-1 correlates with survival of peripheral blood B lymphocytes
Cancer Res, 56 (1), 40-3
PubMed 8548771

Røsok O, Odeberg J, Rode M, Stokke T, Funderud S, Smeland E, Lundeberg J (1996)
Solid-phase method for differential display of genes expressed in hematopoietic stem cells
Biotechniques, 21 (1), 114-21
DOI 10.2144/96211rr02, PubMed 8816245

Rusten LS, Dybedal I, Blomhoff HK, Blomhoff R, Smeland EB, Jacobsen SE (1996)
The RAR-RXR as well as the RXR-RXR pathway is involved in signaling growth inhibition of human CD34+ erythroid progenitor cells
Blood, 87 (5), 1728-36
PubMed 8634418

Smeland E, Fuskevåg OM, Nymann K, Svendesn JS, Olsen R, Lindal S, Bremnes RM, Aarbakke J (1996)
High-dose 7-hydromethotrexate: acute toxicity and lethality in a rat model
Cancer Chemother Pharmacol, 37 (5), 415-22
DOI 10.1007/s002800050406, PubMed 8599863

Publications 1995

Aas-Eng DA, Asheim HC, Deggerdal A, Smeland E, Funderud S (1995)
Characterization of a promoter region supporting transcription of a novel human beta-galactoside alpha-2,6-sialyltransferase transcript in HepG2 cells
Biochim Biophys Acta, 1261 (1), 166-9
DOI 10.1016/0167-4781(94)00250-7, PubMed 7893756

Deggerdal AH, Pettersen F, Kvalheim G, Hornes E, Smeland E, Fodstad O, Hovig E (1995)
Semiquantitative polymerase chain reaction for t(14;18) in follicular lymphomas: a colorimetric approach
Lab Invest, 72 (4), 411-8
PubMed 7723279

Fahlman C, Jacobsen SE, Smeland EB, Lømo J, Naess CE, Funderud S, Blomhoff HK (1995)
All-trans- and 9-cis-retinoic acid inhibit growth of normal human and murine B cell precursors
J Immunol, 155 (1), 58-65
PubMed 7602122

Lømo J, Blomhoff HK, Beiske K, Stokke T, Smeland EB (1995)
TGF-beta 1 and cyclic AMP promote apoptosis in resting human B lymphocytes
J Immunol, 154 (4), 1634-43
PubMed 7836748

Smeland E (1995)
[Physicians liable for military service for sale]
Tidsskr Nor Laegeforen, 115 (24), 3072
PubMed 7570542

Smeland E, Bremnes RM, Fuskevag OM, Aarbakke J (1995)
The effect of calcium channel blockers and calcium on methotrexate accumulation in rat hepatocytes
Anticancer Res, 15 (4), 1221-5
PubMed 7654001

Smeland E, Bremnes RM, Fuskevåg OM, Aarbakke J (1995)
Perturbation of methotrexate transport by verapamil, vinblastine, taurocholate and bromosulfophthalein in rat hepatocytes
Anticancer Res, 15 (1), 45-50
PubMed 7733639

Publications 1994

Aasheim HC, Deggerdal A, Smeland EB, Hornes E (1994)
A simple subtraction method for the isolation of cell-specific genes using magnetic monodisperse polymer particles
Biotechniques, 16 (4), 716-21
PubMed 8024795

Aasheim HC, Loukianova T, Deggerdal A, Smeland EB (1994)
Tissue specific expression and cDNA structure of a human transcript encoding a nucleic acid binding [oligo(dC)] protein related to the pre-mRNA binding protein K
Nucleic Acids Res, 22 (6), 959-64
DOI 10.1093/nar/22.6.959, PubMed 8152927

Christoffersen J, Smeland EB, Stokke T, Taskén K, Andersson KB, Blomhoff HK (1994)
Retinoblastoma protein is rapidly dephosphorylated by elevated cyclic adenosine monophosphate levels in human B-lymphoid cells
Cancer Res, 54 (8), 2245-50
PubMed 8174134

Jacobsen FW, Rothe M, Rusten L, Goeddel DV, Smeland EB, Veiby OP, Slørdal L, Jacobsen SE (1994)
Role of the 75-kDa tumor necrosis factor receptor: inhibition of early hematopoiesis
Proc Natl Acad Sci U S A, 91 (22), 10695-9
DOI 10.1073/pnas.91.22.10695, PubMed 7524102

Jacobsen SE, Fahlman C, Blomhoff HK, Okkenhaug C, Rusten LS, Smeland EB (1994)
All-trans- and 9-cis-retinoic acid: potent direct inhibitors of primitive murine hematopoietic progenitors in vitro
J Exp Med, 179 (5), 1665-70
DOI 10.1084/jem.179.5.1665, PubMed 8163945

Kvalheim G, Jakobsen E, Holte H, Beiske K, Langholm R, Høiby A, Wang MY, Funderund S, Fodstad O, Smeland E (1994)
Autologous bone marrow transplantation of non-Hodgkin's lymphoma patients with marrow purged using immunomagnetic beads
Prog Clin Biol Res, 389, 133-8
PubMed 7700895

Kvaløy SO, Smeland EB (1994)
[Bone marrow transplantation--a constantly developing procedure--requiring updating]
Tidsskr Nor Laegeforen, 114 (3), 302-3
PubMed 8191422

Rasmussen AM, Blomhoff HK, Stokke T, Horejsi V, Smeland EB (1994)
Cross-linking of CD53 promotes activation of resting human B lymphocytes
J Immunol, 153 (11), 4997-5007
PubMed 7963560

Rusten LS, Jacobsen FW, Lesslauer W, Loetscher H, Smeland EB, Jacobsen SE (1994)
Bifunctional effects of tumor necrosis factor alpha (TNF alpha) on the growth of mature and primitive human hematopoietic progenitor cells: involvement of p55 and p75 TNF receptors
Blood, 83 (11), 3152-9
PubMed 7514902

Rusten LS, Jacobsen SE, Kaalhus O, Veiby OP, Funderud S, Smeland EB (1994)
Functional differences between CD38- and DR- subfractions of CD34+ bone marrow cells
Blood, 84 (5), 1473-81
PubMed 7520773

Rusten LS, Smeland EB, Jacobsen FW, Lien E, Lesslauer W, Loetscher H, Dubois CM, Jacobsen SE (1994)
Tumor necrosis factor-alpha inhibits stem cell factor-induced proliferation of human bone marrow progenitor cells in vitro. Role of p55 and p75 tumor necrosis factor receptors
J Clin Invest, 94 (1), 165-72
DOI 10.1172/JCI117303, PubMed 7518828

Smeland E, Bremnes RM, Andersen A, Jaeger R, Eide TJ, Huseby NE, Aarbakke J (1994)
Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat
Cancer Chemother Pharmacol, 34 (2), 119-24
DOI 10.1007/BF00685928, PubMed 8194163

Smeland EB, Rusten L, Jacobsen SE, Skrede B, Blomhoff R, Wang MY, Funderud S, Kvalheim G, Blomhoff HK (1994)
All-trans retinoic acid directly inhibits granulocyte colony-stimulating factor-induced proliferation of CD34+ human hematopoietic progenitor cells
Blood, 84 (9), 2940-5
DOI 10.1182/blood.V84.9.2940.bloodjournal8492940, PubMed 7524761

Publications 1993

Aasheim HC, Aas-Eng DA, Deggerdal A, Blomhoff HK, Funderud S, Smeland EB (1993)
Cell-specific expression of human beta-galactoside alpha 2,6-sialyltransferase transcripts differing in the 5' untranslated region
Eur J Biochem, 213 (1), 467-75
DOI 10.1111/j.1432-1033.1993.tb17783.x, PubMed 8477718

Andersson KB, Deggerdal A, Skjønsberg C, Smeland EB, Blomhoff HK (1993)
Constitutive expression of c-myc does not relieve cAMP-mediated growth arrest in human lymphoid Reh cells
J Cell Physiol, 157 (1), 61-9
DOI 10.1002/jcp.1041570108, PubMed 8408242

Erikstein BK, Holte H, Kvaløy S, Andersson KB, Steen HB, Hannisdal E, Smeland EB (1993)
Expression of CD18 (integrin beta 2 chain) correlates with prognosis in malignant B cell lymphomas
Br J Haematol, 83 (3), 392-8
DOI 10.1111/j.1365-2141.1993.tb04662.x, PubMed 8097923

Jacobsen SE, Veiby OP, Smeland EB (1993)
Cytotoxic lymphocyte maturation factor (interleukin 12) is a synergistic growth factor for hematopoietic stem cells
J Exp Med, 178 (2), 413-8
DOI 10.1084/jem.178.2.413, PubMed 7688022

Slørdahl SH, Smeland EB, Holte H, Grønn M, Lie SO, Seip M (1993)
Leukemic blasts with markers of four cell lineages in Down's syndrome ("megakaryoblastic leukemia")
Med Pediatr Oncol, 21 (4), 254-8
DOI 10.1002/mpo.2950210404, PubMed 8469219

Smeland E, Bremnes RM, Bessesen A, Jaeger R, Aarbakke J (1993)
Interactions of vinblastine and vincristine with methotrexate transport in isolated rat hepatocytes
Cancer Chemother Pharmacol, 32 (3), 209-14
DOI 10.1007/BF00685837, PubMed 8500226

Publications 1992

Blomhoff HK, Smeland EB, Erikstein B, Rasmussen AM, Skrede B, Skjønsberg C, Blomhoff R (1992)
Vitamin A is a key regulator for cell growth, cytokine production, and differentiation in normal B cells
J Biol Chem, 267 (33), 23988-92
PubMed 1429735

Erikstein BK, Funderud S, Beiske K, Aas-Eng A, De Lange Davies C, Blomhoff HK, Smeland EB (1992)
Cell cycle-dependent regulation of CDw75 (beta-galactoside alpha-2,6-sialyltransferase) on human B lymphocytes
Eur J Immunol, 22 (5), 1149-55
DOI 10.1002/eji.1830220507, PubMed 1577059

Rasmussen AM, Smeland EB, Erikstein BK, Caignault L, Funderud S (1992)
A new method for detachment of Dynabeads from positively selected B lymphocytes
J Immunol Methods, 146 (2), 195-202
DOI 10.1016/0022-1759(92)90228-l, PubMed 1371532

Smeland EB (1992)
[Programmed cell death--significance for cancer etiology and treatment]
Tidsskr Nor Laegeforen, 112 (12), 1567
PubMed 1615504

Smeland EB, Beiske K (1992)
[Immunophenotyping of leukemias]
Tidsskr Nor Laegeforen, 112 (18), 2373-4
PubMed 1412241

Smeland EB, Funderud S (1992)
[Sugar molecules, cell adhesion and cancer etiology]
Tidsskr Nor Laegeforen, 112 (22), 2834
PubMed 1412318

Smeland EB, Funderud S, Kvalheim G, Gaudernack G, Rasmussen AM, Rusten L, Wang MY, Tindle RW, Blomhoff HK, Egeland T (1992)
Isolation and characterization of human hematopoietic progenitor cells: an effective method for positive selection of CD34+ cells
Leukemia, 6 (8), 845-52
PubMed 1379314

Smeland EB, Slørdal L (1992)
[Cytokines--from research to clinical use]
Tidsskr Nor Laegeforen, 112 (28), 3544
PubMed 1462323

Stokke T, Holte H, Smeland EB, Lie SO, Steen HB (1992)
Differential chromatin structure-dependent binding of 7-aminoactinomycin D in normal and malignant bone marrow hematopoietic cells
Cancer Res, 52 (18), 5007-12
PubMed 1516056

Publications 1991

Bremnes RM, Smeland E, Huseby NE, Eide TJ, Aarbakke J (1991)
Acute hepatotoxicity after high-dose methotrexate administration to rats
Pharmacol Toxicol, 69 (2), 132-9
DOI 10.1111/j.1600-0773.1991.tb01286.x, PubMed 1775433

Bremnes RM, Smeland E, Slørdal L, Wist E, Aarbakke J (1991)
The effect of vindesine on methotrexate hydroxylation in the rat
Biochem Pharmacol, 42 (8), 1561-8
DOI 10.1016/0006-2952(91)90425-5, PubMed 1930283

Bremnes RM, Smeland E, Willassen NP, Wist E, Aarbakke J (1991)
Inhibition of 7-hydroxymethotrexate formation by amsacrine
Cancer Chemother Pharmacol, 28 (5), 377-83
DOI 10.1007/BF00685693, PubMed 1914082

Erikstein BK, Schwarze P, Blomhoff HK, Funderud S, Stokke T, Smeland EB (1991)
Use of size fractionation of in vitro-activated human B lymphocytes for studies of cell cycle-dependent growth regulation
Scand J Immunol, 33 (1), 51-60
DOI 10.1111/j.1365-3083.1991.tb02491.x, PubMed 1899949

Erikstein BK, Smeland EB, Blomhoff HK, Funderud S, Prydz K, Lesslauer W, Espevik T (1991)
Independent regulation of 55-kDa and 75-kDa tumor necrosis factor receptors during activation of human peripheral blood B lymphocytes
Eur J Immunol, 21 (4), 1033-7
DOI 10.1002/eji.1830210426, PubMed 1850359

Lømo J, Smeland EB, Stokke T, Holte H, Funderud S, Blomhoff HK (1991)
Differential effects of interferon-gamma and low molecular weight BCGF on growth of human B lymphocytes; interferon-gamma prolongs the increased c-MYC mRNA levels after activation
Scand J Immunol, 33 (4), 365-73
DOI 10.1111/j.1365-3083.1991.tb01783.x, PubMed 1902001

Naume B, Nonstad U, Steinkjer B, Funderud S, Smeland E, Espevik T (1991)
Immunomagnetic isolation of NK and LAK cells
J Immunol Methods, 136 (1), 1-9
DOI 10.1016/0022-1759(91)90242-8, PubMed 1704900

Skjønsberg C, Erikstein BK, Smeland EB, Lie SO, Funderud S, Beiske K, Blomhoff HK (1991)
Interleukin-7 differentiates a subgroup of acute lymphoblastic leukemias
Blood, 77 (11), 2445-50
PubMed 2039826

Skrede B, Blomhoff HK, Smeland EB, Wathne KO, Norum KR, Blomhoff R (1991)
Retinyl esters in chylomicron remnants inhibit growth of myeloid and lymphoid leukaemic cells
Eur J Clin Invest, 21 (6), 574-9
DOI 10.1111/j.1365-2362.1991.tb01411.x, PubMed 1778218

Publications 1990

Funderud S, Erikstein B, Asheim HC, Nustad K, Stokke T, Blomhoff HK, Holte H, Smeland EB (1990)
Functional properties of CD19+ B lymphocytes positively selected from buffy coats by immunomagnetic separation
Eur J Immunol, 20 (1), 201-6
DOI 10.1002/eji.1830200129, PubMed 1689662

Helgestad J, Pettersen R, Storm-Mathisen I, Schjerven L, Ulrich K, Smeland EB, Egeland T, Sørskaard D, Brøgger A, Hovig T (1990)
Characterization of a new malignant human T-cell line (PFI-285) sensitive to ascorbic acid
Eur J Haematol, 44 (1), 9-17
DOI 10.1111/j.1600-0609.1990.tb00340.x, PubMed 2307225

Schøyen H, Iversen JG, Smeland EB, Heikkilä R (1990)
A transient acidification linked to intracellular Ca2+ in anti-mu-stimulated human B-lymphocytes
Acta Physiol Scand, 138 (2), 221-7
DOI 10.1111/j.1748-1716.1990.tb08836.x, PubMed 1690498

Skjønsberg C, Kiil Blomhoff H, Gaudernack G, Funderud S, Beiske K, Smeland EB (1990)
Immunological typing of acute leukaemias by rosetting with immunomagnetic beads: comparison with immunofluorescence staining
Scand J Immunol, 31 (5), 567-73
DOI 10.1111/j.1365-3083.1990.tb02807.x, PubMed 2189214

Smeland EB, Holte H, Kiil Blomhoff H, Asheim HC, Stokke T, Torjesen P, Funderud S (1990)
Inhibition of polyphosphoinositide breakdown and c-myc induction accompanying inhibition of human B-cell activation by two monoclonal antibodies against the leucocyte common antigen (CD45)
Scand J Immunol, 31 (5), 583-91
DOI 10.1111/j.1365-3083.1990.tb02809.x, PubMed 1693226

Stamenkovic I, Asheim HC, Deggerdal A, Blomhoff HK, Smeland EB, Funderud S (1990)
The B cell antigen CD75 is a cell surface sialytransferase
J Exp Med, 172 (2), 641-3
DOI 10.1084/jem.172.2.641, PubMed 2373995

Publications 1989

Børresen AL, Brøgger A, Møller P, Smeland E (1989)
[Gene technology in the prevention of cancer]
Tidsskr Nor Laegeforen, 109 (33), 3430-4
PubMed 2609305

Brinch L, Evensen SA, Stavem P, Smeland EB (1989)
[Experiences of immunologic phenotyping in acute leukemia]
Tidsskr Nor Laegeforen, 109 (4), 443-6
PubMed 2919374

Holte H, Blomhoff HK, Beiske K, Funderud S, Torjesen P, Gaudernack G, Stokke T, Smeland EB (1989)
Intracellular events associated with inhibition of B cell activation by monoclonal antibodies to HLA class II antigens
Eur J Immunol, 19 (7), 1221-5
DOI 10.1002/eji.1830190711, PubMed 2547623

Holte H, de Lange Davies C, Beiske K, Stokke T, Marton PF, Smeland EB, Høie J, Kvaløy S (1989)
Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma
Int J Cancer, 44 (6), 975-80
DOI 10.1002/ijc.2910440605, PubMed 2606582

Holte H, Stokke T, Smeland E, Watt R, Blomhoff HK, Kaalhus O, Ohlsson R (1989)
Levels of myc protein, as analyzed by flow cytometry, correlate with cell growth potential in malignant B-cell lymphomas
Int J Cancer, 43 (1), 164-70
DOI 10.1002/ijc.2910430130, PubMed 2642893

Smeland EB, Blomhoff HK, Funderud S, Shalaby MR, Espevik T (1989)
Interleukin 4 induces selective production of interleukin 6 from normal human B lymphocytes
J Exp Med, 170 (4), 1463-8
DOI 10.1084/jem.170.4.1463, PubMed 2677211

Smeland EB, Godal T (1989)
[The 1989 Nobel Prize in physiology and medicine]
Tidsskr Nor Laegeforen, 109 (34-36), 3541-2
PubMed 2694425

Publications 1988

Beiske K, Clark EA, Holte H, Ledbetter JA, Smeland EB, Godal T (1988)
Triggering of neoplastic B cells via surface IgM and the cell surface antigens CD20 and CDw40. Responses differ from normal blood B cells and are restricted to certain morphologic subsets
Int J Cancer, 42 (4), 521-8
DOI 10.1002/ijc.2910420409, PubMed 2459071

Blomhoff HK, Blomhoff R, Stokke T, deLange Davies C, Brevik K, Smeland EB, Funderud S, Godal T (1988)
cAMP-mediated growth inhibition of a B-lymphoid precursor cell line Reh is associated with an early transient delay in G2/M, followed by an accumulation of cells in G1
J Cell Physiol, 137 (3), 583-7
DOI 10.1002/jcp.1041370327, PubMed 2848044

Holte H, Torjesen P, Blomhoff HK, Ruud E, Funderud S, Smeland EB (1988)
Cyclic AMP has the ability to influence multiple events during B cell stimulation
Eur J Immunol, 18 (9), 1359-66
DOI 10.1002/eji.1830180909, PubMed 2458941

Smeland EB (1988)
[Cellular oncogenes. Role in normal cell growth and activation in neoplasms]
Tidsskr Nor Laegeforen, 108 (16), 1299-303
PubMed 3291192

Smeland EB (1988)
[The immunoglobulin gene superfamily]
Tidsskr Nor Laegeforen, 108 (13), 1029-32, 1004
PubMed 2455362

Smeland EB, Blomhoff HK, Ohlsson R, De Lange Davies C, Funderud S, Boye E (1988)
Transcription of protooncogenes during stimulation of normal human B lymphocytes
Eur J Immunol, 18 (11), 1847-50
DOI 10.1002/eji.1830181131, PubMed 3060364

Wathne KO, Norum KR, Smeland E, Blomhoff R (1988)
Retinol bound to physiological carrier molecules regulates growth and differentiation of myeloid leukemic cells
J Biol Chem, 263 (18), 8691-5
PubMed 3163997

Publications 1987

Blomhoff HK, Smeland E, Mustafa AS, Godal T, Ohlsson R (1987)
Epstein-Barr virus mediates a switch in responsiveness to transforming growth factor, type beta, in cells of the B cell lineage
Eur J Immunol, 17 (2), 299-301
DOI 10.1002/eji.1830170224, PubMed 3030769

Blomhoff HK, Smeland EB, Beiske K, Blomhoff R, Ruud E, Bjøro T, Pfeifer-Ohlsson S, Watt R, Funderud S, Godal T (1987)
Cyclic AMP-mediated suppression of normal and neoplastic B cell proliferation is associated with regulation of myc and Ha-ras protooncogenes
J Cell Physiol, 131 (3), 426-33
DOI 10.1002/jcp.1041310315, PubMed 3036888

Holte H, Davies CD, Kvaløy S, Smeland EB, Foss-Abrahamsen A, Kaalhus O, Marton PF, Godal T (1987)
The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomas
Int J Cancer, 39 (5), 590-4
DOI 10.1002/ijc.2910390508, PubMed 3106247

Lømo J, Holte H, de Lange Davies C, Ruud E, Laukas M, Smeland EB, Godal T, Blomhoff HK (1987)
Downregulation of c-myc RNA is not a prerequisite for reduced cell proliferation, but is associated with G1 arrest in B-lymphoid cell lines
Exp Cell Res, 172 (1), 84-91
DOI 10.1016/0014-4827(87)90095-4, PubMed 3115797

Smeland EB (1987)
Regulation of human B cell growth in vitro
The Norwegian Radium Hospital/The Norwegian Cancer Society, Oslo, 1 b. (flere pag.)
BIBSYS 874163404, ISBN 82-90187-34-3

Smeland EB, Beiske K, Ek B, Watt R, Pfeifer-Ohlsson S, Blomhoff HK, Godal T, Ohlsson R (1987)
Regulation of c-myc transcription and protein expression during activation of normal human B cells
Exp Cell Res, 172 (1), 101-9
DOI 10.1016/0014-4827(87)90097-8, PubMed 3308492

Smeland EB, Beiske K, Ohlsson R, Holte H, Ruud E, Blomhoff HK, Jefferis R, Godal T (1987)
Activation of human B cells: alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells
J Immunol, 138 (10), 3179-84
PubMed 3553323

Smeland EB, Blomhoff HK, Holte H, Ruud E, Beiske K, Funderud S, Godal T, Ohlsson R (1987)
Transforming growth factor type beta (TGF beta) inhibits G1 to S transition, but not activation of human B lymphocytes
Exp Cell Res, 171 (1), 213-22
DOI 10.1016/0014-4827(87)90264-3, PubMed 2442015

Publications 1986

Dahl-Jørgensen K, Brinchmann-Hansen O, Hanssen KF, Ganes T, Kierulf P, Smeland E, Sandvik L, Aagenaes O (1986)
Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study
Br Med J (Clin Res Ed), 293 (6556), 1195-9
DOI 10.1136/bmj.293.6556.1195, PubMed 3096429

Lea T, Smeland E, Funderud S, Vartdal F, Davies C, Beiske K, Ugelstad J (1986)
Characterization of human mononuclear cells after positive selection with immunomagnetic particles
Scand J Immunol, 23 (4), 509-19
DOI 10.1111/j.1365-3083.1986.tb03083.x, PubMed 2422741

Smeland EB, Godal T (1986)
IgG subclasses in lymphomas
Monogr Allergy, 19, 164-8
PubMed 3762542

Smeland EB, Godal T, Beiske K, Watt R, Pfeifer-Ohlsson S, Ohlsson R (1986)
Regulation of c-myc mRNA and protein levels during activation of normal human B cells
Curr Top Microbiol Immunol, 132, 290-6
DOI 10.1007/978-3-642-71562-4_43, PubMed 3539537

Publications 1985

Andersen HT, Smeland EB, Owe JO, Myhre K (1985)
Analyses of maximum cardiopulmonary performance during exposure to acute hypoxia at simulated altitude--sea level to 5000 meters (760-404 mm Hg)
Aviat Space Environ Med, 56 (12), 1192-7
PubMed 4084174

Godal T, Davies C, Smeland EB, Heikkilä R, Funderud S, Steen HB, Hildrum K (1985)
Antibodies to surface IgM and IgD increase the expression of various class II antigens on human B cells
Eur J Immunol, 15 (2), 173-7
DOI 10.1002/eji.1830150212, PubMed 3871699

Heikkilä R, Iversen JG, Smeland E, Godal T (1985)
Intracellular Ca2+ buffering potentiates an 86Rb+ permeability response in human lymphocytes
Acta Physiol Scand, 124 (2), 247-51
DOI 10.1111/j.1748-1716.1985.tb07658.x, PubMed 3925725

Smeland E, Funderud S, Ruud E, Kiil Blomhoff H, Godal T (1985)
Characterization of two murine monoclonal antibodies reactive with human B cells. Their use in a high-yield, high-purity method for isolation of B cells and utilization of such cells in an assay for B-cell stimulating factor
Scand J Immunol, 21 (3), 205-14
DOI 10.1111/j.1365-3083.1985.tb01422.x, PubMed 3887557

Smeland E, Godal T, Ruud E, Beiske K, Funderud S, Clark EA, Pfeifer-Ohlsson S, Ohlsson R (1985)
The specific induction of myc protooncogene expression in normal human B cells is not a sufficient event for acquisition of competence to proliferate
Proc Natl Acad Sci U S A, 82 (18), 6255-9
DOI 10.1073/pnas.82.18.6255, PubMed 3929253

Publications 1984

Bjøro T, Gaarder PI, Smeland EB, Kornstad L (1984)
Thyroid antibodies in blood donors: prevalence and clinical significance
Acta Endocrinol (Copenh), 105 (3), 324-9
DOI 10.1530/acta.0.1050324, PubMed 6702401

Smeland EB, Jefferis R, Godal T (1984)
Surface IgG subclasses in human B cell lymphomas as revealed by monoclonal antibodies
Clin Exp Immunol, 57 (1), 163-70
PubMed 6378459

Smeland EB, Owe JO, Andersen HT (1984)
Modification of the 'dividing bradycardia' by hypoxia or exercise
Respir Physiol, 56 (2), 245-51
DOI 10.1016/0034-5687(84)90108-7, PubMed 6463431

Page visits: 38049